Refined Oncology is a clinical stage biotechnology company focused on developing RO-202, a LILRB4 monoclonal antibody targeting aberrant myeloid cells in hematological malignancies

Pioneering myeloid cell targeting therapeutics for the treatment of oncology and autoimmune diseases

Learn More

Targeting significant unmet needs in hematological malignancies

Chronic myelomonocytic leukemia (CMML) is a rare blood cancer classified as an MDS/MPN overlap neoplasm as it exhibits features of both ineffective and abnormal blood cell production and overproduction of monocytic cells. Critically, CMML carries a significant risk of progression, with approximately a quarter of patients progressing to aggressive Acute Myeloid Leukemia (AML). There are limited treatment options for patients with CMML, with standard of care consisting of hypomethylating agents.

A clinically validate cell surface target to eradicate malignant monocytes and resistant cell populations

Leukocyte Immunoglobulin-like Receptor B4 (LILRB4), is a cell-surface protein highly expressed on monocytes and macrophages, which functions as an immune checkpoint that suppresses immune responses, primarily by inhibiting T-cell activation. In hematologic malignancies, its expression is significantly increased on neoplastic monocytic cells in both CMML and monocytic AML, where it is associated with a poor prognosis by both shielding the cancer from the immune system and promoting tumor survival and infiltration.

RO-202, a phase 2 ready mAb targeting LILRB4

Our asset, RO-202, is a first-in-class humanized Fc-active IgG1 anti-LILRB4 mAb designed to deplete malignant monocytic cells in Chronic Myelomonocytic Leukemia (CMML), MDS, and monocytic Acute Myeloid Leukemia (AML).

RO-202 has completed a Phase 1 study and has shown promising efficacy in CMML patients. We have Orphan Drug Designation and Fast Track Designation from the FDA.